Habitat-based radiomics from contrast-enhanced CT and clinical data to predict lymph node metastasis in clinical N0 peripheral lung adenocarcinoma ≤ 3 cm
- PMID: 40379768
- PMCID: PMC12084560
- DOI: 10.1038/s41598-025-02181-x
Habitat-based radiomics from contrast-enhanced CT and clinical data to predict lymph node metastasis in clinical N0 peripheral lung adenocarcinoma ≤ 3 cm
Abstract
This study aims to develop an integrated model combining habitat-based radiomics and clinical data to predict lymph node metastasis in patients with clinical N0 peripheral lung adenocarcinomas measuring ≤ 3 cm in diameter. We retrospectively analyzed 1132 patients with lung adenocarcinoma from two centers who underwent surgical resection with lymph node dissection and had preoperative computed tomography (CT) scans showing peripheral nodules ≤ 3 cm. Multivariable logistic regression was employed to identify independent risk factors for the clinical model. Radiomics and habitat models were constructed by extracting and analyzing radiomic features and habitat regions from contrast-enhanced CT images. Subsequently, a combined model was developed by integrating habitat-based radiomic features with clinical characteristics. Model performance was evaluated using the area under the receiver operating characteristic curve (AUC). The habitat model exhibited promising predictive performance for lymph node metastasis, outperforming other standalone models with AUCs of 0.962, 0.865, and 0.853 in the training, validation, and external test cohorts, respectively. The combined model demonstrated superior discriminative ability, achieving the highest AUCs of 0.983, 0.950, and 0.877 for the training, validation, and external test cohorts, respectively. The integration of habitat-based radiomic features with clinical data offers a non-invasive approach to assess the risk of lymph node metastasis, potentially supporting clinicians in optimizing patient management decisions.
Keywords: Habitat imaging; Lymph node metastasis; Peripheral lung adenocarcinomas; Radiomics.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Competing interests: The authors declare no competing interests.
Figures








Similar articles
-
2.5D deep learning radiomics and clinical data for predicting occult lymph node metastasis in lung adenocarcinoma.BMC Med Imaging. 2025 Jul 1;25(1):225. doi: 10.1186/s12880-025-01759-1. BMC Med Imaging. 2025. PMID: 40597741 Free PMC article.
-
Prediction of pathological nodal involvement by CT-based Radiomic features of the primary tumor in patients with clinically node-negative peripheral lung adenocarcinomas.Med Phys. 2018 Jun;45(6):2518-2526. doi: 10.1002/mp.12901. Epub 2018 Apr 29. Med Phys. 2018. PMID: 29624702 Free PMC article.
-
Integrative nomogram of intratumoral, peritumoral, and lymph node radiomic features for prediction of lymph node metastasis in cT1N0M0 lung adenocarcinomas.Sci Rep. 2021 May 24;11(1):10829. doi: 10.1038/s41598-021-90367-4. Sci Rep. 2021. PMID: 34031529 Free PMC article.
-
Value of Presurgical 18F-FDG PET/CT Radiomics for Predicting Mediastinal Lymph Node Metastasis in Patients with Lung Adenocarcinoma.Cancer Biother Radiopharm. 2024 Oct;39(8):600-610. doi: 10.1089/cbr.2022.0038. Epub 2022 Nov 4. Cancer Biother Radiopharm. 2024. PMID: 36342812
-
Predictive value of radiomic features extracted from primary lung adenocarcinoma in forecasting thoracic lymph node metastasis: a systematic review and meta-analysis.BMC Pulm Med. 2024 May 18;24(1):246. doi: 10.1186/s12890-024-03020-x. BMC Pulm Med. 2024. PMID: 38762472 Free PMC article.
References
-
- Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J. Clin.74, 229–263. 10.3322/caac.21834 (2024). - PubMed
-
- Leiter, A., Veluswamy, R. R. & Wisnivesky, J. P. The global burden of lung cancer: current status and future trends. Nat. Rev. Clin. Oncol.20, 624–639. 10.1038/s41571-023-00798-3 (2023). - PubMed
-
- Beigelman-Aubry, C., Dunet, V. & Brun, A. L. CT imaging in pre-therapeutic assessment of lung cancer. Diagn. Interv. Imaging. 97, 973–989. 10.1016/j.diii.2016.07.010 (2016). - PubMed
-
- Park, H. K. et al. Occult nodal metastasis in patients with non-small cell lung cancer at clinical stage IA by PET/CT. Respirology15, 1179–1184. 10.1111/j.1440-1843.2010.01793.x (2010). - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical